Anti-RMDN3 antibody produced in rabbit

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

RMDN3 (regulator of microtubule dynamics 3) protein is involved in cell differentiation and apoptosis. Methylation status of this gene′s promoter determines its expression, which is increased in prostate cancer. In human muscle cells, the expression of this protein is dependent on the differentiation stage. The increase in the expression of this protein is correlated with the increase in proteins involved in advanced stages of myotubal differentiation, namely sarcoplasmic reticulum Ca²⁺ ATPase and myosin heavy-chain protein. RMDN3 is expressed in basal cell carcinoma, squamous cell carcinoma and the peritumoral tissue, and thus, might be a key player in the pathogenesis of keratinocyte carcinoma.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

RMDN3 (regulator of microtubule dynamics 3) was first identified by using a bait protein TCPTP (T-cell protein tyrosine phosphatase) in a yeast two hybrid screen. It has two binding sites for 14-3-3 proteins called conserved region 1 and conserved region 2. This protein has a molecular weight of 52,118Da, and is composed of 470 amino acids. This gene is localized to human chromosome 15q15.1, and is composed of 12 exons.

Protein FAM82C (Protein tyrosine phosphatase-interacting protein 51) (TCPTP-interacting protein 51) (Cerebral protein 10).

Corresponding Antigen APREST71998

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany